Sonnet BioTherapeutics Holdings Inc. (SONN)

Business: Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action.

IPO Date: 31-Oct-2006

Founder, Chairman. CEO & Pres: Dr. Pankaj Mohan Ph.D.

Chief Scientific Officer & Co-Founder: Dr. John K. Cini Ph.D.

Listing: NASDAQ: SONN

Country: United States

Headquarters: Princeton, NJ

Website: https://www.sonnetbio.com

Market cap: $16.30 Mln

Revenue (TTM): $0.71 Mln

Earnings (TTM): $-27.48 Mln

Cash: $13.64 Mln

Total Debt: $0.08 Mln

Insider's Holding: 3.17%

Liquidity: Low

52 Week range: $0.23 - 2.07

Shares outstanding: 60,587,900

10 Years Aggregate:

• CFO: $-52.48 Mln
• EBITDA: $-67.45 Mln
• Net Profit: $-101.61 Mln